Matrix Metalloproteinase 11 is a Potential Biomarker in Bladder Cancer Diagnosis and Prognosis

Chen Chen,Xiaoping Liu,Jiazhi Jiang,Shenjuan Li,Gang Wang,Lingao Ju,Fubing Wang,Tongzu Liu,Sheng Li
DOI: https://doi.org/10.2147/ott.s243452
IF: 4
2020-09-01
OncoTargets and Therapy
Abstract:PURPOSE: Bladder cancer is one of the leading causes of cancer death all over the world, and half of patients are diagnosed at advanced stages with poor therapeutic response. Thus, developing new biomarkers for bladder cancer diagnosis and prognosis is urgently needed.MATERIALS AND METHODS: Bioinformatic and gene ontology (GO) analysis were employed to screen highly upregulated and secretory tumor markers in the TCGA BLCA cohort. IHC in tissue microarray and ELISA in cancer cell culture medium were used to validate the expression of putative biomarkers in bladder cancer. Bisulfite sequencing was used to detect DNA methylation status in the promoter of putative genes.RESULTS: In this study, MMP11 is first identified as one of the most differentially expressed genes (DEGs) in bladder cancer by meta-analysis in a TCGA bladder cancer cohort. The strong upregulation of MMP11 is confirmed at protein levels in both bladder cancer patients and cell lines. Mechanistic studies reveal that MMP11 promoter hypomethylation, but not genomic amplification or mutation, accounts for its enhanced expression in bladder cancer both in vitro and in vivo. Moreover, clinicopathological analysis indicates that MMP11 upregulation is associated with the tumor progression and poor survival in bladder cancer patients.DISCUSSION: These findings suggest that MMP11, as a secretory protein, is a promising biomarker for diagnosis and prognosis in bladder cancer.
oncology,biotechnology & applied microbiology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is the development of biomarkers for the diagnosis and prognosis of bladder cancer. Specifically, through big - data analysis and bioinformatics methods, the researchers screened out tumor markers that are highly up - regulated in bladder cancer and have secretory properties, and finally determined matrix metalloproteinase 11 (MMP11) as a potential biomarker for the diagnosis and prognosis of bladder cancer. The paper discusses in detail the up - regulation of MMP11 expression in bladder cancer and its relationship with the clinicopathological characteristics of patients, and reveals that the mechanism of MMP11 up - regulation is mainly related to the hypomethylation state of its promoter region. ### Research Background - Bladder cancer is one of the leading causes of cancer death worldwide. Approximately half of the patients are diagnosed at an advanced stage and have a poor response to treatment. - Current diagnostic methods such as cystoscopy and urine cytology are reliable, but they are invasive or lack sensitivity, especially in the detection of early - stage cancers. - Therefore, it is particularly urgent to develop new, highly sensitive, specific, and non - invasive biomarkers for the diagnosis and prognosis of bladder cancer. ### Research Objectives - Screen out tumor markers that are highly up - regulated in bladder cancer and have secretory properties through big - data analysis and bioinformatics methods. - Verify the expression of the selected biomarker in bladder cancer and its correlation with clinicopathological characteristics. - Explore the molecular mechanism of the up - regulation of the selected biomarker expression. ### Main Findings - **Up - regulation of MMP11 expression**: MMP11 is significantly up - regulated in bladder cancer tissues and cell lines, and its expression level gradually increases with the progression of tumor staging. - **Relationship between MMP11 and clinicopathological characteristics**: High expression of MMP11 is significantly associated with advanced tumor staging, recurrence, metastasis, high - grade disease, and non - papillary subtypes in bladder cancer patients. - **Mechanism of MMP11 up - regulation**: The up - regulation of MMP11 expression is mainly attributed to the hypomethylation state of its promoter region, rather than gene mutation or amplification. - **Relationship between MMP11 and patient survival**: High expression of MMP11 is significantly associated with poor prognosis in bladder cancer patients, including a decrease in overall survival rate and recurrence - free survival rate. ### Conclusions - As a secreted protein, MMP11 has important application potential in the diagnosis and prognosis of bladder cancer. - This study provides a theoretical basis and experimental evidence for the further development of non - invasive diagnostic methods based on MMP11.